Search

Displaying results 3551 - 3560 of 8469 in total
  1. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … [L15153] The life cycle of head lice (_Pediculus capitis_) is approximately 30 days, seven to twelve of which are spent as eggs laid on hair shafts near the scalp.

  2. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and

  3. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    The compound was proposed to bind to the reductase enzyme and was named compactin. … It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins.

  4. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing.

  5. Drug

    Perflenapent

    go.drugbank.com/drugs/DB11625
    ApprovedInvestigationalWithdrawn

    Dodecafluoropentane is also known as perfluoropentane or perflenapent.

  6. Drug

    Picric acid

    go.drugbank.com/drugs/DB03651
    Approved

    Used as antiseptic, astringent, and stimulant for epitheliazation.

  7. Drug

    Iron isomaltoside 1000

    go.drugbank.com/drugs/DB12208
    ApprovedInvestigationalWithdrawn

    Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.

  8. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    Panitumumab was granted FDA approval on 27 September 2006.[L17663]

  9. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [L51998,L52043] In July 2025, its indication was expanded to include all patients with hemophilia A or B, regardless of the presence of inhibitors.[L53653]

  10. Drug

    Interferon beta-1a

    go.drugbank.com/drugs/DB00060
    ApprovedInvestigational

    It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced.